Company Introduces Smaller 7 French Compatible Atherectomy Catheter

Tue, 10/06/2009 - 6:56am


The device is now available to treat a larger patient population

KIRKLAND, WA––August 10, 2009––Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral arterial disease (PAD), today introduced the 7 French compatible version of its peripheral atherectomy catheter. Jetstream G2™ NXT is based on the company’s state-of-the-art catheter technology capable of treating the entire spectrum of disease found in patients suffering from PAD, including hard and soft plaque, calcium, fibrotic lesions and thrombus. 7 French compatibility allows physicians to use Jetstream G2 NXT in the treatment of PAD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology. 

“The 7 French compatible Jetstream G2 NXT is nearly identical to Jetstream G2, but has the advantages associated with smaller sheath technology,” said Dr. Robert Bersin at Seattle Cardiology. “As such, it expands my ability to treat more anatomies and patients with varying degrees of PAD.”

Approximately 12 million Americans suffer from the effects of PAD and many in this rapidly expanding patient population go undiagnosed. Commonly associated with high blood pressure, diabetes, heart disease, stroke and aging, PAD causes a build-up of plaque within the arteries that limits blood flow to the extremities. PAD can lead to severe limb pain, non-healing ulcers and critical limb ischemia and, if left untreated, can lead to gangrene, amputation and even death. The most common intervention for PAD has historically included highly-invasive procedures, including bypass surgery. Unfortunately, many patients are poor surgical candidates for whom surgery can be life threatening. Atherectomy—the removal of the blockage by inserting a specialized catheter into the artery to remove the fatty buildup from the artery walls—has proven to be an effective, first-line option in minimally invasive PAD intervention. Yet, until now, atherectomy devices have not been effective in removing all types of hard and soft tissue plaque.

“Today’s news coupled with the recent FDA clearance to market Jetstream G2 for thrombus removal underscores our unwavering commitment to provide new and better treatment options for the millions of Americans suffering from PAD,” commented Pathway Medical Technologies President and CEO Paul Buckman. “With the introduction of Jetstream G2 NXT, we are able to provide much needed atherectomy treatment to an expanded patient population.”

For further information, visit the company’s at



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.